ACL Digital Acquires Symbiance to Boost AI-Driven Clinical Research

ACL Digital has acquired Symbiance, a US-based Contract Research Organization (CRO), to expand its clinical research capabilities, announced in a press release. This strategic acquisition strengthens ACL Digital's position in the clinical research sector by integrating Symbiance's expertise in clinical data services, medical monitoring, and pharmacovigilance.

The acquisition aims to enhance ACL Digital's life sciences portfolio by combining its AI-powered offerings with Symbiance's deep domain expertise. This integration is expected to provide comprehensive, data-driven solutions for global pharmaceutical, biotech, and medical device companies. Ramandeep Singh, CEO of ACL Digital, emphasized that the acquisition aligns with the company's growth strategy, aiming to deliver transformative solutions that meet the industry's AI transformation needs.

Symbiance, known for its 'people + product' delivery model, will contribute its proprietary tools and AI-powered analytics to boost ACL Digital's service offerings. This move underscores ACL Digital's commitment to advancing as a global leader in digital solutions for clinical research, enabling clients to adopt intelligent, data-driven solutions for improved outcomes.